TriLink Enters into Distribution Agreement with Astral Scientific

"With TriLink's unique product offering and Astral's commitment to bringing new technologies to the Australian diagnostic and research markets, we feel this is a great opportunity to support important scientific advancements. We are proud to join forces with the Astral Scientific team," stated TriLink CEO, Richard Hogrefe, Ph.D.

"We are excited to represent TriLink in Australia and offer their exceptional range of modified nucleoside triphosphates, custom oligos and CleanAmp™ PCR products to our research customers," commented Rick de Leeuw, Managing Director at Astral.
This agreement will provide researchers in the Australian market access to high quality, modified nucleic acid products to further advance their efforts.